Neuronetics (STIM) Q2 2026: Greenbrook Revenue Surges 17% Driving Margin Expansion and Cash Flow Improvement
Neuronetics advanced its path to profitability by leveraging Greenbrook’s robust growth and evolving NeuroStar’s commercial model, improving margins and significantly reducing cash burn. Operational discipline in clinic management and expanded customer options for NeuroStar systems underpin a strategic shift positioning the company for sustainable growth amid emerging interventional psychiatry therapies.
Summary
- Clinic Network Optimization: Greenbrook’s operational improvements and revenue cycle management drove strong revenue and margin gains.
- Commercial Model Evolution: NeuroStar broadened customer access via new capital purchase and leasing options, balancing support levels with market demand.
- Interventional Psychiatry Leadership: Strategic positioning for upcoming psychedelic therapies leverages existing infrastructure and expertise.
Business Overview
Neuronetics is a leader in interventional mental health, combining its NeuroStar transcranial magnetic stimulation (TMS) technology with direct patient care through its Greenbrook network of interventional psychiatry clinics. The company generates revenue primarily through NeuroStar system sales and treatment sessions alongside Greenbrook’s clinic services, which include TMS and Spravato therapies for treatment-resistant depression.
Performance Analysis
For Q2 2026, Neuronetics reported total revenue of $41.6 million, up 9.1% year-over-year, driven predominantly by a 16.8% increase in Greenbrook revenue to $26.9 million. NeuroStar revenue declined slightly by 2.7% to $14.7 million, reflecting a strategic shift in its commercial model. Gross margin expanded notably to 51.1%, up from 46.6% a year earlier, supported by improved revenue cycle management at Greenbrook and a favorable shift in NeuroStar revenue mix towards capital sales.
Operating expenses declined 12% to $22.7 million, largely due to reductions in general and administrative and sales and marketing costs, signaling effective cost discipline. The company’s adjusted EBITDA swung positive to $0.3 million from a $5.6 million loss in the prior year, while net loss narrowed significantly to $3.4 million from $10.1 million. Cash used in operations and investing fell to $1.4 million, down from $3.8 million, underscoring improved cash flow dynamics.
- Greenbrook Revenue Growth: Strong provider growth and pricing initiatives drove top-line and margin expansion.
- NeuroStar Model Shift: Introduction of capital purchase and lease options broadened customer base despite session revenue decline.
- Cost Efficiency Gains: Operating expense reductions and improved revenue cycle management enhanced profitability metrics.
The quarter reflects a deliberate repositioning of Neuronetics’ business model, balancing growth in its clinic network with evolving customer preferences for NeuroStar system acquisition, while maintaining a disciplined cost structure aimed at achieving sustained profitability and positive cash flow.
Executive Commentary
"This was a quarter of real operational progress, and meaningful steps toward our goal of sustained profitability and positive net cash flow from operations and investing. For some time, NeuroStar has not competed to its full potential, and we are changing that by broadening how customers can access our technology while we continue to drive operational gains across the Greenbrook clinics."
Dan Revers, President and Chief Executive Officer
"We grew revenue, improved our margins, reduced our cash burn, and strengthened our balance sheet all while continuing to invest in the growth of the business. Our focus is on converting that progress into sustained profitability and positive operating cash flow."
Nir Nair, Chief Financial Officer
Strategic Positioning
1. Diversified NeuroStar Access Models
Neuronetics expanded its go-to-market approach by offering customers three distinct acquisition options for NeuroStar systems: outright purchase with a la carte support, lease financing with flexible commitments, and the traditional treatment session partnership model with full support. This diversification aligns with varied customer preferences and enables the company to compete across a broader market, capturing sales previously inaccessible under a single model.
2. Greenbrook Clinic Operational Excellence
Greenbrook demonstrated robust growth fueled by improved revenue cycle management, including better patient qualification, cleaner claims, and enhanced payer contracting, supported by AI-driven insurance authorization. The clinic network’s fixed cost structure benefits from increased occupancy and patient throughput, creating leverage for margin expansion and cash generation.
3. Leadership in Emerging Interventional Psychiatry Therapies
Neuronetics is strategically positioned to capitalize on the anticipated commercial launch of psychedelic therapies such as Compass Pathways’ COMP360 psilocybin. Greenbrook’s existing infrastructure, including REMS certification and trained clinical staff, provides a scalable platform for safe, in-office administration of these new treatments, complementing its offerings of TMS and Spravato therapies.
4. Strengthened Management Team and Organizational Alignment
Recent leadership changes, including the appointment of Nir Nair as CFO with a proven track record of driving profitability, and promotions within Greenbrook and sales leadership, reflect a focused effort to enhance operational execution and strategic clarity. The flattening of organizational structure aims to increase agility and closer oversight of business details.
5. Financial Discipline and Cash Flow Focus
Neuronetics narrowed its full-year revenue guidance and raised gross margin expectations, while lowering operating expense forecasts excluding stock-based compensation. Updated cash flow guidance now includes investing activities, targeting a reduced net cash outflow and emphasizing the transition toward positive operating cash flow as a key milestone.
Key Considerations
Neuronetics’ Q2 results highlight a pivotal transition in both commercial strategy and operational execution, with several critical factors shaping its trajectory:
- Customer Choice Impact: The shift to multiple NeuroStar acquisition models introduces revenue recognition complexity but broadens market reach.
- Clinic Capacity Utilization: Greenbrook clinics have approximately 40% unutilized capacity, presenting immediate growth potential before new site expansion.
- Emerging Therapy Readiness: Early investments in infrastructure and partnerships position Neuronetics to lead in psychedelic treatment delivery.
- Cost Management Sustainability: Continued expense discipline is essential to translate revenue gains into sustained profitability.
- Cash Flow Optimization: Improved cash conversion from operations and investing activities reduces financing risk and supports strategic investments.
Risks
Despite progress, Neuronetics faces risks including potential delays in regulatory approval and commercial adoption of psychedelic therapies, competitive pressures in the TMS market, and reimbursement uncertainties. The transition in NeuroStar’s revenue mix may cause near-term volatility in reported financials. Execution risks remain around scaling clinic operations and maintaining operational efficiencies.
Forward Outlook
For Q3 2026, Neuronetics expects continued revenue growth driven by Greenbrook and expanded NeuroStar commercial models, with gross margin sustained between 48% and 50%. Operating expenses are projected between $23.75 million and $25 million quarterly, excluding stock-based compensation. The company targets cash flow from operations and investing to remain within the narrowed full-year range of negative $10.5 million to negative $14.5 million.
- Total revenue guidance narrowed to $160 million to $164 million for FY 2026.
- Operating expenses expected between $91 million and $96 million excluding stock-based compensation.
Management emphasizes disciplined execution on patient acquisition cost efficiency and operational leverage as key drivers for the remainder of the year.
Takeaways
Neuronetics’ Q2 results reveal a company actively reshaping its business model and operational foundation to achieve sustainable profitability in a rapidly evolving interventional psychiatry landscape.
- Strategic Commercial Shift: The introduction of capital purchase and leasing options for NeuroStar reflects a pragmatic response to diverse customer needs, enabling penetration into previously untapped segments and potential margin improvement through higher capital sales.
- Clinic Network as Growth Engine: Greenbrook’s strong revenue growth and improved cash collections underscore the value of operational discipline and technology-enabled revenue cycle management in scaling clinic profitability.
- Future Growth Catalysts: Positioning for emerging psychedelic therapies leverages existing REMS infrastructure and clinical expertise, offering a differentiated platform to capture new market opportunities as regulatory approvals progress.
Conclusion
Neuronetics demonstrated meaningful operational and financial progress in Q2 2026, balancing growth in its clinic network with a strategic evolution of its NeuroStar commercial approach. With enhanced leadership and disciplined cost management, the company is well positioned to advance toward sustained profitability and capitalize on emerging interventional psychiatry therapies.
Industry Read-Through
Neuronetics’ results and strategic initiatives highlight broader trends in mental health treatment, where integrated care delivery and diversified commercial models are critical to capturing evolving patient and provider demands. The company’s early readiness for psychedelic therapies signals a potential inflection point for interventional psychiatry, emphasizing the importance of scalable clinic infrastructure and regulatory compliance. Other players in the sector should monitor Neuronetics’ approach to revenue model diversification and operational efficiency as benchmarks for navigating the transition to next-generation mental health treatments.